The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Centers for Disease Control and Prevention's vaccine advisory committee wrapped up the first day of its meeting since ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

With the CDC director's chair still empty, HHS Secretary Robert F. Kennedy Jr. endorsed recommendations made months ago by ...

Merck's Enflonsia vaccine is the second RSV monoclonal antibody that is recommended for approval to prevent RSV. The Food and ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers.

RSV vaccine access expanded to some people in their 50s, according to CDC website The decision appears on a CDC webpage but wasn’t on the agency’s official adult immunization schedule.